G Protein-Coupled Receptor

A G protein-coupled receptor (GPCR)—also designated a seven-transmembrane (7TM) receptor or heptahelical serpentine receptor—is an integral cell membrane protein that converts extracellular chemical or physical signals (photons, odorants, neurotransmitters, hormones, chemokines, and lipids) into intracellular biochemical responses via heterotrimeric guanine nucleotide-binding proteins (G proteins) and arrestin scaffolds. Encoded by more than 800 distinct genes (~4% of the protein-coding human genome), GPCRs represent the largest superfamily of membrane receptors in eukaryotes and serve as the direct molecular targets for approximately 34–35% of all small-molecule and peptide drugs approved by the U.S. Food and Drug Administration (FDA).

Every GPCR shares a conserved transmembrane topology consisting of an extracellular amino (N)-terminus, seven membrane-spanning hydrophobic α-helices (TM1 through TM7) connected by three intracellular loops (ICL1–ICL3) and three extracellular loops (ECL1–ECL3), and an intracellular carboxyl (C)-terminus (frequently anchored to the inner bilayer leaflet by a palmitoylated eighth amphipathic helix, H8). For elucidating the biochemical pharmacology and high-resolution X-ray crystal structures of the β₂-adrenergic receptor (β₂AR) in complex with its heterotrimeric G_s protein, Robert J. Lefkowitz and Brian K. Kobilka were awarded the 2012 Nobel Prize in Chemistry.

The GRAFS / A–F Superfamily Taxonomy

Based on phylogenetic sequence conservation and extracellular ligand-binding domain architecture, human GPCRs are classified into four major classes (corresponding to the GRAFS system: Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin):

1. Class A (Rhodopsin-like, ~700 human receptors, including ~400 olfactory receptors): The largest class, binding amines (epinephrine, dopamine, serotonin, acetylcholine at muscarinic receptors), peptides (opioids, angiotensin, chemokines), purines, and retinal (in visual rhodopsin). The orthosteric ligand-binding pocket typically resides deep within the outer half of the 7TM helical bundle. Class A receptors feature highly conserved microswitch motifs, including the E/DRY (Glu/Asp-Arg-Tyr) motif at the cytoplasmic end of TM3, the CWxP toggle switch in TM6, and the NPxxY motif in TM7.
2. Class B (Secretin and Adhesion families, ~48 receptors): Divided into B1 (Secretin-like, 15 receptors)—which bind large endocrine peptides such as glucagon, glucagon-like peptide-1 (GLP-1), parathyroid hormone (PTH), and calcitonin via a ~120–160-residue extracellular N-terminal domain—and B2 (Adhesion GPCRs, 33 receptors), which possess massive extracellular adhesion domains cleaved autocatalytically at a GPCR proteolysis site (GPS) to expose a tethered Stachel agonist peptide.
3. Class C (Metabotropic Glutamate / Family C, 22 receptors): Includes metabotropic glutamate receptors (mGluR1–8), GABA_B receptors, extracellular Ca²⁺-sensing receptors (CaSR), and sweet/umami taste receptors (TAS1R). Class C GPCRs function as obligate homodimers or heterodimers (e.g., GABA_B1/GABA_B2) and capture ligands within a large bilobed extracellular Venus flytrap domain (VFTD) linked to the 7TM core via a cysteine-rich domain.
4. Class F (Frizzled / Smoothened, 11 receptors): Mediate canonical and non-canonical Wnt and Hedgehog developmental morphogen signaling, possessing an extracellular cysteine-rich Wnt-binding domain or sterol-binding pocket.

Conformational Mechanics of TM6 Outward Movement

In the basal inactive state, a Class A GPCR is stabilized by an intramolecular ionic lock—a salt bridge between the conserved Arg^3.50 of the TM3 DRY motif and an acidic residue (Glu^6.30) at the cytoplasmic base of TM6—holding the intracellular helical bundle closed. When an extracellular agonist binds the orthosteric pocket, it shifts the rotamer state of Trp^6.48 in the TM6 CWxP motif and rearranges a hydrophobic core triad (P^5.50–I^3.40–F^6.44). Because TM6 contains a conserved proline kink, this perturbation is amplified toward the cytoplasm: the intracellular end of TM6 swings outward by 10 to 14 Å accompanied by a ~30° helical rotation and an inward shift of TM7 (NPxxY motif). This outward displacement of TM6 breaks the ionic lock and opens a deep cytoplasmic cavity between TM3, TM5, TM6, and ICL2 that accommodates the C-terminal α5 helix of the heterotrimeric Gα subunit.

Receptor-Catalyzed Nucleotide Exchange and GTPase Hydrolysis

Heterotrimeric G proteins assemble on the cytoplasmic leaflet of the plasma membrane as a complex of three distinct subunits: a guanine nucleotide-binding Gα subunit (39–52 kDa, comprising a Ras-like GTPase domain and an α-helical domain) and an obligate, tightly bound Gβγ heterodimer (~36 kDa β-propeller and ~8 kDa prenylated γ subunit).

In the resting state, Gα binds guanosine diphosphate (GDP), which clamps the Ras-like and α-helical domains together and maintains high-affinity binding to Gβγ, masking effector-interaction surfaces on both subcomplexes. Upon binding an agonist-activated GPCR, the receptor acts as a guanine nucleotide exchange factor (GEF): engagement of the Gα C-terminal α5 helix into the receptor's cytoplasmic cleft allosterically disorders the Gα P-loop and β6–α5 loop, opening the interdomain cleft and lowering GDP affinity by several orders of magnitude. Because intracellular GTP concentrations (~100–500 μM) far exceed GDP concentrations (~10–50 μM), GTP rapidly binds the empty nucleotide pocket. Coordination of the γ-phosphate of GTP induces a conformational switch in three flexible regions of Gα (Switch I, II, and III), causing the Gα–GTP subunit and the Gβγ dimer to dissociate from the receptor and from each other.

Both active Gα–GTP and free Gβγ diffuse along the inner membrane leaflet to modulate downstream enzymes and ion channels. Signal termination relies on the intrinsic GTPase activity of the Gα subunit, which hydrolyzes bound GTP back to GDP + P_i, triggering reassociation of Gα–GDP with Gβγ. Because intrinsic Gα GTPase rates are relatively slow (k_cat ≈ 0.02–0.2 s⁻¹), physiological termination (such as millisecond recovery in retinal photoreceptors or cardiac pacemakers) is accelerated up to 1,000-fold by Regulators of G-protein Signaling (RGS) proteins, which function as GTPase-activating proteins (GAPs) by stabilizing the transition state of GTP hydrolysis.

The Four Canonical Gα Subfamilies

Human genomes encode 16 Gα genes grouped into four functional subfamilies based on sequence homology and primary effector coupling:

To prevent toxic overstimulation during prolonged agonist exposure, GPCRs undergo rapid homologous desensitization within seconds to minutes. Once a receptor adopts its active conformation, G protein-coupled receptor kinases (GRK1–GRK7) selectively recognize and phosphorylate multiple serine and threonine residues on the receptor's C-terminal tail and ICL3 (forming a phosphorylation "barcode"). These phosphorylated clusters recruit cytosolic arrestins (visual arrestin-1 and -4 in photoreceptors; ubiquitous β-arrestin-1 and β-arrestin-2 in non-visual tissues).

Binding of β-arrestin to the phosphorylated GPCR core performs three distinct functions:

1. Steric Uncoupling: The finger loop of β-arrestin inserts into the exact cytoplasmic TM6 cleft occupied by the Gα α5 helix, sterically blocking further G-protein activation.
2. Receptor Endocytosis: β-arrestin binds clathrin heavy chains and the AP-2 adaptor complex, targeting the GPCR into clathrin-coated pits for endocytosis into early endosomes (from which the receptor is either dephosphorylated and recycled to the plasma membrane or sorted to lysosomes for degradation, termed downregulation).
3. Arrestin-Mediated Signaling & Biased Agonism: β-arrestins act as independent multiprotein scaffolds that recruit mitogen-activated protein kinase (MAPK) cascades (Raf-1, MEK1, ERK1/2) and c-Src. Because G-protein coupling and β-arrestin recruitment rely on distinct subsets of receptor conformational states, synthetic biased ligands can selectively stabilize one pathway over the other—a central paradigm in modern pharmacology aimed at separating therapeutic efficacy from on-target side effects.

How does one GPCR molecule amplify an extracellular signal by several orders of magnitude?

Signal amplification occurs sequentially at multiple enzymatic tiers. First, a single agonist-bound GPCR (or photoactivated rhodopsin molecule) can catalytically activate dozens to hundreds of Gα subunits per second before being desensitized by GRK/β-arrestin. Second, each active Gα_s–GTP binds an adenylyl cyclase enzyme that converts hundreds of ATP molecules into cyclic AMP (cAMP) per second. Third, cAMP activates Protein Kinase A (PKA), each catalytic subunit of which phosphorylates hundreds of downstream substrate proteins, yielding an overall gain of 10⁴ to 10⁶.

How do cholera toxin and pertussis toxin disrupt GPCR signaling in opposite ways through the same G-protein target class?

Both bacterial toxins are ADP-ribosyltransferases that covalently attach an ADP-ribose group from intracellular NAD⁺ onto specific Gα subunits, but with opposite functional consequences. Cholera toxin (from Vibrio cholerae) modifies Arg²⁰¹ in the catalytic site of Gα_s, abolishing its intrinsic GTPase activity so Gα_s remains locked in the active GTP-bound state, driving runaway cAMP production and CFTR Cl⁻/water secretion in intestinal epithelia. Pertussis toxin (from Bordetella pertussis) modifies a C-terminal cysteine on Gα_i/o, preventing the GPCR from binding Gα_i and locking it in the inactive GDP-bound state, which removes inhibitory restraint on adenylyl cyclase.

What is the difference between an inverse agonist and a neutral antagonist at a GPCR?

Many GPCRs exhibit constitutive (basal) activity, spontaneously isomerizing between inactive (R) and active (*R*\*) states even in the complete absence of an endogenous agonist. A neutral antagonist binds equally well to both R and *R*\* states, blocking agonist binding without altering basal receptor signaling. An inverse agonist (such as most clinical antihistamines at the H₁ receptor or β-blockers like ICI-118,551 at β₂AR) preferentially binds and stabilizes the inactive R conformation, reducing constitutive G-protein signaling below the basal unliganded level.

1. Rasmussen, S. G., et al. (2011). "Crystal structure of the β₂ adrenergic receptor–G_s protein complex." Nature, 477(7366), 549–555. https://doi.org/10.1038/nature10361
2. Weis, W. I., & Kobilka, B. K. (2018). "The molecular basis of G protein–coupled receptor activation." Annual Review of Biochemistry, 87, 897–919. https://doi.org/10.1146/annurev-biochem-060614-033910
3. Hauser, A. S., Attwood, M. M., Rask-Andersen, M., Schiöth, H. B., & Gloriam, D. E. (2017). "Trends in GPCR drug discovery: new agents, targets and indications." Nature Reviews Drug Discovery, 16(12), 829–842. https://doi.org/10.1038/nrd.2017.178
4. Pierce, K. L., Premont, R. T., & Lefkowitz, R. J. (2002). "Seven-transmembrane receptors." Nature Reviews Molecular Cell Biology, 3(9), 639–650. https://doi.org/10.1038/nrm908